Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Q3 2025 value amounting to -$0.13.

  • Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) fell 55000.0% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 14166.67%. This contributed to the annual value of -$0.09 for FY2024, which is 2264.96% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported EPS (Weighted Average and Diluted) of -$0.13 as of Q3 2025, which was down 55000.0% from -$0.13 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$0.02 for Q4 2024, and its period low was -$9.12 during Q1 2021.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.55, with a median of -$0.04 in 2022.
  • Data for Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY increase of 9993.01% (in 2021) and a maximum YoY decrease of 1611551.72% (in 2021) over the last 5 years.
  • Lineage Cell Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.05 in 2021, then skyrocketed by 35.81% to -$0.03 in 2022, then grew by 8.99% to -$0.03 in 2023, then surged by 40.54% to -$0.02 in 2024, then plummeted by 700.77% to -$0.13 in 2025.
  • Its last three reported values are -$0.13 in Q3 2025, -$0.13 for Q2 2025, and -$0.02 during Q1 2025.